PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 401–500 of 1,001
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor
Dhupar, R., Kraak, L. V. D., Pennathur, A., Schuchert, M. J., Nason, K. S., Luketich, J. D., & Lotze, M. T. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2016.12.011 · Cited by 43
The role of PD‐1 in regulation of macrophage apoptosis and its subversion by Leishmania donovani
Roy, S., Gupta, P., Palit, S., Basu, M., Ukil, A., & Das, P. K. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.12 · Cited by 48
Mitsuhashi, A., & Okuma, Y. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1827-7 · Cited by 45
Current Treatment of Melanoma Brain Metastasis
Rishi, A., & Yu, H.-H. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00733-z · Cited by 44
Hasegawa, S., Ikesue, H., Nakao, S., Shimada, K., Mukai, R., Tanaka, M., Matsumoto, K., Inoue, M., Satake, R., Yoshida, Y., et al. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5108 · Cited by 49
“The PD-1 pathway in T-cells is involved with the tumor microenvironment.(43) CTLA-4 is expressed by activated T-cells.”
BackgroundMarín‐Jiménez, J. A., Capasso, A., Lewis, M. S., Bagby, S. M., Hartman, S. J., Shulman, J., Navarro, N. M., Yu, H., Rivard, C. J., Wang, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607282 · Cited by 46
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 48
“Polymorphisms in PD-1/PD-L1 genes in humans have been associated with a range of autoimmune diseases including type 1 diabetes, systemic lupus erythematosus and multiple sclerosis (64).”
BackgroundProtein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
Dai, W., Zhang, J., Li, S., He, F., Liu, Q., Gong, J., Yang, Z., Gong, Y. Q., Tang, F., Wang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865964 · Cited by 52
Zhu, J., Wen, H., Ju, X., Bi, R., Zuo, W., & Wu, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170879 · Cited by 44
Moreira, J., Tobias, A. O., O’Brien, M. P., & Agulnik, M. (2017) · Drugs · doi:10.1007/s40265-017-0734-0 · Cited by 50
Shiba, M., Inaba, H., Ariyasu, H., Kawai, S., Inagaki, Y., Matsuno, S., Iwakura, H., Yamamoto, Y., Nishi, M., & Akamizu, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9518-17 · Cited by 42
“Anti-PD-1 and anti-PD-L1 antibodies activate CD8 and CD4T-cells, thereby strengthening cytotoxic and helper/inducer activity, respectively (2).”
BackgroundInfluentialLymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma
Yip, R. H. L., Lee, L. H., Schaeffer, D. F., Horst, B. A. J., & Yang, H.-M. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000502 · Cited by 45
Dai, M., Liu, M., Yang, H., Küçük, C., & You, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00356-0 · Cited by 53
Immunology of β-Cell Destruction
Torre, D. L., & Lernmark, Å. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_24 · Cited by 49
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick, B. S., Herbst, R. S., & Goldberg, S. B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.955794 · Cited by 43
“Recruiting SHP-2 produces an inhibitory signal, blocking downstream effects of PI3K and Akt [20], culminating in cell-cycle arrest and suppressed T-cell activation [21].”
BackgroundGrowth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression
Chen, L., Yi, X., Goswami, S., Ahn, Y., Roybal, J. D., Yang, Y., Diao, L., Peng, D., Peng, D. H., Fradette, J. J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234570 · Cited by 46
“Evidence shows that functional tumor cell killing by tumor-infiltrating T cells can be inhibited by both the CTLA-4 and PD-1 co-inhibitory signals, and that tumor cells frequently express PD-L1, which can negatively signal T cells through both the PD-1 and B7-1 molecules on their surface.(40,52) Our data show that BMP…”
BackgroundZhao, Y., Jia, Y., Li, C., Shao, R., & Fang, Y. (2018) · Shock · doi:10.1097/shk.0000000000001171 · Cited by 42
Wang, Y., Zheng, K., Xiong, H., Huang, Y., Chen, X., Zhou, Y., Qin, W., Su, J., Chen, R., Qiu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762989 · Cited by 48
“Programmed death 1 (PD-1) 60 protein is a co-inhibitory receptor on the surface of activated T cells [21].”
BackgroundImmune Checkpoint Blockade in Hepatocellular Carcinoma
Liu, G.-J., Wang, W., Lu, M.-D., Xie, X.-Y., Xu, H.-X., Xu, Z.-F., Chen, L.-D., Wang, Z., Liang, J.-Y., Huang, Y., et al. (2015) · Liver Cancer · doi:10.1159/000367758 · Cited by 41
Xu, Y., Hao, X., Ren, Y., Xu, Q., Liu, X., Song, S., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1063423 · Cited by 50
Penaloza‐MacMaster, P., Provine, N. M., Blass, E., & Barouch, D. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403237 · Cited by 45
Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance
Wang, Y., Zhuang, Q., Zhou, S., Hu, Z., & Lan, R. (2009) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-009-0116-2 · Cited by 42
Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer
Tang, P. A., & Heng, D. Y. C. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0284-2 · Cited by 42
“Programmed death 1 (PD-1) is another T cell coinhibitory receptor [8, 9] with two known ligands, PD-L1 (B7-H1 or CD274) [10, 11] and PD-L2 (B7-DC or CD273) [12, 13].”
BackgroundLee, J., Kefford, R. F., & Carlino, M. S. (2016) · Immunotherapy · doi:10.2217/imt-2016-0022 · Cited by 44
Kim, S., Nam, S. J., Park, C., Kwon, D., Yim, J., Song, S. G., Ock, C.-Y., Kim, Y. A., Park, S., Kim, T. M., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1626653 · Cited by 46
“apoptosis, anergy, and functional exhaustion; in this way, tumor cells evade immune surveillance.(7,8) PD-1/PD-L1 pathway blockades showed a considerable antitumor effect in”
BackgroundMi, Y., Han, J., Zhu, J., & Jin, T. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02495-7 · Cited by 48
“The two ligands share 40% identical amino acids [14].”
BackgroundPolyaniline-Based Glyco-Condensation on Au Nanoparticles Enhances Immunotherapy in Lung Cancer
Su, W., Chang, L.-C., Song, W.-H., Yang, L., Wang, L., Chia, Z., Chin, Y., Shan, Y.-S., Huang, C., & Yeh, C. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c03839 · Cited by 43
Lan, Y., Wang, H., Chen, A., & Zhang, J. (2022) · Immunology · doi:10.1111/imm.13517 · Cited by 46
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40
“PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) are two common ligands of PD-1, both of which can be expressed across the cell surface [39, 40].”
BackgroundGenetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine
Duan, J., Wu, Y., Liu, J., Zhang, J., Fu, Z., Feng, T., Liu, M., Han, J., Li, Z., & Chen, S. (2019) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s224849 · Cited by 42
“The PD-1 ligands PD-L1 and PD-L2 were discovered in 2000.(87) Studies have shown that PD-1 and PD-L2 can block T cell activation, proliferation and the production of cytokines, such as interferon-γ (IFN-γ), thereby exerting a negative immune-modulatory effect which results in immunosuppression.”
BackgroundPD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
Zhang, S., Minaguchi, T., Xu, C., Qi, N., Itagaki, H., Shikama, A., Tasaka, N., Akiyama, A., Sakurai, M., Ochi, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6545-9 · Cited by 43
Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches
Yura, Y., & Hamada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311179 · Cited by 50
Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 43
Age‐dependent hypoxia‐induced PD‐L1 upregulation in patients with obstructive sleep apnoea
Cubillos‐Zapata, C., Balbás‐García, C., Ortiz, J. A., Toledano, V., Torres, M., Almendros, I., Casitas, R., Zamarrón, E., García‐Sánchez, A., Feliú, J., et al. (2019) · Respirology · doi:10.1111/resp.13470 · Cited by 42
Xu, D., Dong, P., Xiong, Y., Chen, R., Konno, Y., Ihira, K., Yue, J., & Watari, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.598205 · Cited by 39
Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment
Pramanik, A., & Bhattacharyya, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120755 · Cited by 44
Wasik, M. A., Zhang, Q., Marzec, M., Kasprzycka, M., Wang, H. Y., & Liu, X. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.02.007 · Cited by 42
Exosome therapeutics for non-small cell lung cancer tumorigenesis
Orooji, N., Fadaee, M., Kazemi, T., & Yousefi, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03544-6 · Cited by 41
“CAF, Cancer Associated Fibroblasts; TAM, Tumor Associated Macrophage in both cancer cells and TME cell populations, and the programmed cell death protein 1 (PD-1) receptor, which appears on activated T cells [23].”
BackgroundWang, J. M., Cheng, J., Li, G. Y., Wu, X. Y., Thayer, P., Greer, P., Smith, A. M., High, K. P., Moorman, J. P., & Yao, Z. Q. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.03.003 · Cited by 41
Yan, K., Sun, D., Jiang, G., Kaplan, H. J., & Shao, H. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0610332 · Cited by 41
“PD-L1 and PD-L2 have overlapping functions and can act synergistically to inhibit T cell activation, proliferation, and cytokine production, and PD-L1 plays a predominant role in vivo [14, 15].”
BackgroundContribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy
Li, Y., Wang, J., Li, C., & Ke, X. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.673228 · Cited by 38
Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
Zhu, H., Qin, H., Huang, Z., Li, S., Zhu, X., He, J., Yang, J. L., Yu, X., & Yi, X. (2015) · PubMed · Cited by 42
Oxygen-dependent regulation of immune checkpoint mechanisms
Ohta, A. (2018) · International Immunology · doi:10.1093/intimm/dxy038 · Cited by 39
Helper-like innate lymphoid cells and cancer immunotherapy
Crinier, A., Vivier, É., & Bléry, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.002 · Cited by 42
Ghamari, S., Abbasi‐Kangevari, M., Tayebi, T., Bahrami, S., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00180 · Cited by 40
“In addition, hAECs and hAMSCs neither express the Programmed Death-1 (PD-1), an inhibitory receptor that is generally expressed on activated T and B cells, nor Programmed Death Ligand 1 and 2 (PDL-1/2) (Okazaki and Honjo, 2007; Wu et al., 2014).”
BackgroundRETRACTED: How microRNAs affect the PD-L1 and its synthetic pathway in cancer
Danbaran, G. R., Aslani, S., Sharafkandi, N., Hemmatzadeh, M., Hosseinzadeh, R., Azizi, G., Jadidi‐Niaragh, F., Babaie, F., & Mohammadi, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106594 · Cited by 36
RetractedPD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review)
Li, C.-J., Lin, L., Hou, M., & Chu, P. (2020) · Oncology Reports · doi:10.3892/or.2020.7831 · Cited by 42
“PD-L1 is a member of the B7 superfamily and a type I transmembrane glycoprotein (26,27).”
BackgroundTranscriptional and epigenetic regulation of PD-1 expression
Chi, Z., Lü, Y., Yang, Y., Li, B., & Lu, P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03737-y · Cited by 42
Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Yang, W., Lei, C., Song, S., Jing, W., Jin, C., Gong, S., Tian, H., & Guo, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02299-8 · Cited by 43
“Its extracellular domain shares 21–33% sequence homology with CTLA-4, CD28, and ICOS [7, 8].”
BackgroundCourtney, A. N., Thapa, P., Singh, S., Wishahy, A. M., Zhou, D., & Sastry, K. J. (2011) · European Journal of Immunology · doi:10.1002/eji.201041359 · Cited by 38
Rajasalu, T., Brosi, H., Schuster, C., Spyrantis, A., Boehm, B. O., Chen, L., Reimann, J., & Schirmbeck, R. (2010) · Diabetes · doi:10.2337/db09-1135 · Cited by 42
“regulate the balance between T-cell activation, tolerance, and immunopathology (19,39).”
BackgroundCurrent Perspectives on Immunotherapy
Weber, J. S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.003 · Cited by 43
Tajaldini, M., Poorkhani, A., Amiriani, T., Amiriani, A., Javid, H., Aref, P., Ahmadi, F., Sadani, S., & Khori, V. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175991 · Cited by 40
Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer.
Savabkar, S., Azimzadeh, P., Chaleshi, V., Mojarad, E. N., & Aghdaei, H. A. (2013) · Gastroenterology and hepatology from bed to bench. · Cited by 37
Fu, G., Polyakova, O., MacMillan, C., Ralhan, R., & Walfish, P. G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.031 · Cited by 37
“…PD-L1/PD-1 pathway played a role in inhibiting Tcell receptor (TCR) mediated cell growth and cytokine production, resulting in peripheral tolerance of cancer cells and a failure to recognize and destroy the foreign cancer cells (Freeman et al., 2000; Blank et al., 2005; Okazaki and Honjo, 2007).”
BackgroundScognamiglio, T., & Chen, Y.-T. (2017) · Head and Neck Pathology · doi:10.1007/s12105-017-0857-3 · Cited by 35
Urabe, F., Kosaka, N., Yoshioka, Y., Egawa, S., & Ochiya, T. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0176-z · Cited by 42
“Regarding the immune escape system, many types of cancer cells upregulate the expression of programmed death-1 ligand (PD-L1), which plays an important role in blocking the immune system by binding to PD-1 expressed on the surface of T cells and induces programmed death in activated T cells [55].”
BackgroundPhosphoinositide 3‐kinase δ is a regulatory T‐cell target in cancer immunotherapy
Lim, E. L., & Okkenhaug, K. (2019) · Immunology · doi:10.1111/imm.13082 · Cited by 43
MR1-Restricted T Cells Are Unprecedented Cancer Fighters
Vacchini, A., Chancellor, A., Spagnuolo, J., Mori, L., & Libero, G. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00751 · Cited by 38
Wang, X., Ji, Q., Yan, X., Lian, B., Si, L., Chi, Z., Sheng, X., Kong, Y., Mao, L., Bai, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.546604 · Cited by 40
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Singh, V., Khurana, A., Allawadhi, P., Banothu, A. K., Bharani, K. K., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790963 · Cited by 43
“dysfunctional T-cell displayed a good expression of CD127, which possibly suggests a lower functional exhaustion (Okazaki and Honjo, 2007).”
BackgroundHope, J. L., Otero, D. C., Bae, E., Stairiker, C. J., Palete, A. B., Faso, H. A., Lin, M. P., Henriquez, M. L., Roy, S. B., Seo, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112436 · Cited by 48
Gallez-Hawkins, G. M., Thao, L., Palmer, J. M., Dagis, A., Li, X., Franck, A. E., Tegtmeier, B., Lacey, S. F., Diamond, D. J., Forman, S. J., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.03.022 · Cited by 44
“This inhibitory response in the presence of chronic antigenic stimulation is presumably protective, and the absence of PD-1 and the associated autoimmune diseases [4] suggests a role for PD-1 in prevention of immunopathology.”
BackgroundImproved survival after induction of sepsis by cecal slurry in PD-1 knockout murine neonates
Young, W. A., Fallon, E. A., Heffernan, D. S., Efron, P. A., Cioffi, W. G., & Ayala, A. (2016) · Surgery · doi:10.1016/j.surg.2016.11.008 · Cited by 37
Niu, B., Appleby, T. C., Wang, R., Morar, M., Voight, J., Villaseñor, A. G., Clancy, S., Wise, S. J., Belzile, J.-P., Papalia, G. A., et al. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00822 · Cited by 39
Regulation of PD-L1 Trafficking from Synthesis to Degradation
Lemma, E. Y., Letian, A., Altorki, N. K., & McGraw, T. E. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0953 · Cited by 47
“Its dysregulation can lead to a wide array of diseases, such as lupuslike syndrome, type 1 diabetes mellitus, and loss of fetomaternal tolerance in mice (9).”
BackgroundLiu, C., Jiang, J., Gao, L., Hu, X., Wang, F., Shen, Y., Yu, G., Zhao, Z., & Zhang, X. (2014) · International Journal of Genomics · doi:10.1155/2014/247637 · Cited by 36
“and several SNPs have been linked to development of autoimmunity in various populations [10].”
BackgroundInfluentialLiu, Y., Guo, H., Zhao, L., & Wang, J. (2014) · PubMed Central · Cited by 36
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 41
“This event enables the binding of the protein tyrosine phosphatase SHP-2, which dephosphorylates downstream effector molecules, such as ZAP70 and CD3zeta, thereby limiting TCR-dependent T cell activation.”
BackgroundInfluentialInhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA
Kundu, K., Ghosh, S., Sarkar, R., Edri, A., Brusilovsky, M., Gershoni‐Yahalom, O., Yossef, R., Shemesh, A., Soria, J., Lazar, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0023 · Cited by 36
Lin, D. J., Ng, J. C. K., Huang, L., Robinson, M., O’Hara, J., Wilson, J. A., & Mellor, A. L. (2021) · Clinical Otolaryngology · doi:10.1111/coa.13794 · Cited by 40
Peña‐Cruz, V., McDonough, S. M., Diaz‐Griffero, F., Crum, C. P., Carrasco, R. D., & Freeman, G. J. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.127 · Cited by 48
“PD-1 (CD279) is a CD28 family member expressed on activated T and B cells, as well as some myeloid cells (Okazaki and Honjo, 2007).”
BackgroundDerigs, M., Heers, H., Lingelbach, S., Hofmann, R. W., & Hänze, J. (2022) · Immunologic Research · doi:10.1007/s12026-022-09302-y · Cited by 36
“However, in sepsis, this process can be overactive and impair T cell function favoring immunosuppression [16].”
BackgroundAnalysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates
Zasada, M., Lenart, M., Rutkowska-Zapała, M., Stec, M., Durlak, W., Grudzień, A., Krzeczkowska, A., Mól, N., Pilch, M., Siedlar, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186819 · Cited by 37
“It is one of the key negative regulators of the immune response, maintains immune tolerance [11], prevents development of autoimmune diseases [12], and controls extend of healthy tissue damage during infection [13].”
BackgroundLiver Toxicity with Cancer Checkpoint Inhibitor Therapy
Nadeau, B. A., Fecher, L. A., Owens, S. R., & Razumilava, N. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1667358 · Cited by 37
Parise, I. Z. S., Parise, G. A., de Noronha, L., Surakhy, M., Woiski, T. D., Silva, D. B., Costa, T. E.-J. B., Del-Valle, M. H. C. P., Komechen, H., Rosati, R., et al. (2019) · Cancers · doi:10.3390/cancers11111730 · Cited by 40
“This escape is usually mediated by elevated binding of the PD-L1 antigen in tumors to PD-1 receptors in CTL [34].”
BackgroundStrategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 38
Curcumin analog GO‐Y030 boosts the efficacy of anti‐PD‐1 cancer immunotherapy
Maruyama, T., Kobayashi, S., Shibata, H., Chen, W., & Owada, Y. (2021) · Cancer Science · doi:10.1111/cas.15136 · Cited by 37
The Immunomodulation Potential of Exosomes in Tumor Microenvironment
Wang, M., & Zhang, B. (2021) · Journal of Immunology Research · doi:10.1155/2021/3710372 · Cited by 39
“The interaction between programmed death-ligand 1 (PD-L1) in cancer cells and programmed cell death protein 1 (PD-1) receptor in activated T cells is another mechanism of immune evasion in cancer [61].”
BackgroundHepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances
Ding, Z., Wang, L., Sun, J., Zheng, L., Tang, Y., & Tang, H. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526206 · Cited by 49
“This protein can bind to its ligands PD-L1 and PD-L2, which are expressed in many tumors, including HCC, transmitting inhibitory signals to T cells and inducing immune evasion by tumor cells (140).”
The role of programmed cell death‐1 (PD‐1) and its ligands in pediatric cancer
van Dam, L. S., de Zwart, V., & Meyer‐Wentrup, F. A. G. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25284 · Cited by 35
“PD-L1 is expressed by a wide variety of tumors and expression is often associated with poor prognosis [2,3,14,16,22] (Table II).”
BackgroundProgrammed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors
Kumar, S. R., Kim, D. Y., Henry, C. J., Bryan, J. N., Robinson, K. L., & Eaton, A. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12297 · Cited by 36
“PD-L1 plays an important role in inducing and maintaining immune tolerance to self-antigens and protects normal tissues from excessive damage and autoimmune complications.(19,20) Although PDL1 expression has been identified in the cells such as B-lymphocytes, FIGURE 4 Programmed death ligand 1 (PDL-1), signal transduc…”
BackgroundWang, W., Lam, W., & Chen, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2260-7 · Cited by 34
A carrier-free multiplexed gene editing system applicable for suspension cells
Ju, A., Lee, S. W., Lee, Y. E., Han, K.-C., Kim, J., Shin, S. C., Park, H. J., Kim, E. E., Hong, S., & Jang, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119298 · Cited by 36
Londoño, M., Reig, M., & on behalf of the RETOINMUNO Multidisciplinary Group (2020) · Cancers · doi:10.3390/cancers12113446 · Cited by 33
The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle
Masoumi, E., Tahaghoghi-Hajghorbani, S., Jafarzadeh, L., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.018 · Cited by 35
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications
Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022) · Immunology · doi:10.1111/imm.13573 · Cited by 40
“encoded PD-1 protein, mainly expressed in activated T/B lymphocytes, NK cells, monocytes, dendritic cells, and mesenchymal stem cells [65].”
BackgroundChakravarti, N., & Prieto, V. G. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.12.10 · Cited by 39
“The binding of PD-L1 or PD-L2 leads to recruitment of tyrosine phosphatases generating an inhibitory signal that blocks downstream effects of PI3K/Akt signaling resulting in cell cycle arrest and suppressed T-cell activation (21,42,43).”
BackgroundMolecular Markers for Colorectal Cancer
Wright, M., Beaty, J. S., & Ternent, C. A. (2017) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.01.014 · Cited by 39
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
Galligan, A., Xu, W., Fourlanos, S., Nankervis, A. J., Chiang, C. Y., Mant, A. M., Parente, P., Rischin, D., Krishnamurthy, B., Sandhu, S. K., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13762 · Cited by 33
High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β
Ullah, M., Azzazen, D., Kaci, R., Benabbou, N., Pujade-Lauraine, É., Pocard, M. D., & Mirshahi, M. (2019) · Neoplasia · doi:10.1016/j.neo.2019.01.001 · Cited by 35
“Among the mechanisms set in motion by tumors to cape the immune system, programmed cell death protein-1 (PD-1) [10] d cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) [11] are ready described.”
BackgroundChen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 38
Recent developments in cancer research: Expectations for a new remedy
Ando, K., Hu, Q., Kasagi, Y., Oki, E., & Mori, M. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12440 · Cited by 33
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
Venglár, O., Bago, J., Motais, B., Hájek, R., & Jelínek, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816499 · Cited by 36
Quinn, J., Salman, A., Paluch, C., Jackson-Wood, M., McClements, M. E., Luo, J., Davis, S. J., Cornall, R. J., MacLaren, R. E., Dendrou, C. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68401-y · Cited by 32
“PD-L1 has been studied as one of the mechanisms by which pigmented cells of the uvea are capable of suppressing T cell activation in vitro, and is upregulated in response to inflammatory cytokines 6,7,41 .”
Nivolumab in the treatment of malignant melanoma: review of the literature
Nakamura, M., Mashima, E., Yamaguchi, T., Sasaki, N., Hara, Y., Omoto, D., Haruyama, S., Yoshioka, M., Nishio, D., Sakuragi, Y., et al. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s62102 · Cited by 39
“a novel protein involved in programmed cell death.(7,8) The group used a murine 2B4.”
BackgroundThe Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
Glorieux, C., Xia, X., & Huang, P. (2021) · Cancers · doi:10.3390/cancers13174426 · Cited by 37
“Human PD-L1 is composed of 290 amino acids, shares 40% amino acid identity with human PD-L2 and 70% with its murine ortholog [8].”
BackgroundInfluentialType 1 diabetes related to immune checkpoint inhibitors
Tachibana, M., & Imagawa, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101657 · Cited by 35
Haas, K. M., Poe, J. C., & Tedder, T. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901218 · Cited by 37
“receptor signaling on both B and T cells (12, 13), is thought to negatively regulate TI-2 Ab responses because PD-1 / mice ex-”
Background
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.